Despite the extensive recent focus on its cost, insulin use in the United States remains dominated by insulin glargine and other analogs, as well as pen devices for delivery, new research shows.
The findings come from a nationally representative audit of outpatient care with input from nearly 5000 physicians who prescribed insulin to patients with type 2 diabetes in 2016-2020.
